Pharmiweb ChannelsAll | PharmaCo | Clinical Research | R&D/BioTech | Sales/Mktg | Healthcare | Recruitment | Pharmacy | Medical Comms

Pharmiweb.com RSS Feed Pharmiweb.com RSS Feeds

Advertising

Press Release

PCI Biotech: First half year 2017 report and presentation

PCI Biotech Holding
Posted on: 29 Aug 17

Oslo, 29 August 2017 - Please find enclosed the financial report and presentation for second quarter and first half year 2017.

PCI Biotech reported important progress for the fima Chem programme during 1H 2017, with early promising signs of effect in Phase I. The study has also provided encouraging interim overall survival data averaging 15.6 months per end July 2017 (median 14.4 months), with 25% of the patients still being alive. These promising results may be further strengthened by repeating the treatment. Safety for repeated treatment will be investigated in a Phase I extension study and the first patient in this study was treated in August. Regulatory interactions to clarify the fastest way to market and subsequent preparations for Phase II will run in parallel with the extension study, thereby minimising time to initiation of a potential pivotal Phase II study with repeated treatment.

Clinical translation of the fima Vacc asset is progressing with tolerability being established and the initial results on overall T-cell responses from the study are expected to be available during 2H 2017.

The fima NAc programme has showed positive progress and the research collaborations with RXi Pharmaceuticals and a top-10 pharma company have both entered into new stages during 2017.

The rights issue completed in Q1 2017 enables PCI Biotech to progress the fima Chem programme through regulatory interactions to determine the fastest way to market, as well as the Phase I extension study and other preparations for initiation of Phase II. The proceeds, together with a grant from the Norwegian Research Council, will also cover the clinical translation of the promising fima Vacc asset. The organisation will be strengthened with Dr Olivecrona as Chief Medical Officer (CMO) from October 2017.

Per Walday, CEO of PCI Biotech, comments: "After the rapid initiation of the fimaChem Phase I extension study, we now have full focus on effective completion of this study and the regulatory interactions to clarify fastest route to market. We are also eagerly awaiting the initial results on overall T-cell responses from the fimaVacc Phase I study and will revert to the market as soon as these are available."

Highlights

fima Chem

  • Encouraging interim overall survival data from Phase I
  • First patient treated in the Phase I extension study

fima Vacc  

  • Tolerability of the vaccination technology established - awaiting initial results on overall T-cell responses

fima NAc

  • RXi Pharmaceuticals collaboration expanded into the field of immuno-oncology
  • Top-10 pharma collaboration extended and entered into in vivo studies

Corporate

  • Dr Hans Olivecrona appointed as Chief Medical Officer
  • Completion of a fully underwritten rights issue of NOK 70 million
  • Awarded up to NOK 14.3 million in public grants for further development of the vaccination platform

A presentation in English will be held today, Tuesday 29 August 2017, at Oslo Cancer Cluster Innovation Park.

Time: Tuesday August 29 2017, 09.00am -10.00am CEST (local time).
Venue:  Jónas  Einarsson  aud.  (2nd  floor,  entrance  2B), Oslo Cancer Cluster
Innovation Park, Ullernchausséen 64, Oslo.

The presentation can be followed as a live audiocast, see link ( http://webtv.hegnar.no/presentation.php?webcastId=58639798 ). It will be possible to post questions through the webcast console.

About PCI Biotech          
PCI Biotech is a biopharmaceutical company focusing on development and commercialisation of novel therapies for the treatment of cancer through its innovative photochemical internalisation (PCI) technology platform. PCI is applied to three distinct anticancer paradigms: fima Chem (enhancement of chemotherapeutics for localised treatment of cancer), fima Vacc (T-cell induction technology for therapeutic vaccination), and fima NAc (nucleic acid therapeutics delivery).
Photochemical internalisation induces triggered endosomal release that is used to unlock the true potential of a wide array of therapeutic modalities. The company's lead fima Chem programme consists of a Phase I/II clinical study in bile duct cancer, an orphan indication with a high unmet need and without approved products. fima Vacc applies a unique mode of action to enhance the essential cytotoxic effect of therapeutic cancer vaccines, which works in synergy with several other state-of-the-art vaccination technologies. fima NAc utilises the endosomal release to provide intracellular delivery of nucleic acids, such as mRNA and siRNA therapeutics, thereby addressing one of the major bottlenecks facing this emerging and promising field.
For more information visit: www.pcibiotech.com

Contact information: PCI Biotech Holding ASA, Ullernchausséen 64, N-0379 Oslo                
Ronny Skuggedal, CFO, rs@pcibiotech.no, Mobile: +47 9400 5757

Forward-looking statements  
This announcement may contain forward-looking statements, which as such are not historical facts, but are based upon various assumptions, many of which are based, in turn, upon further assumptions. These assumptions are inherently subject to significant known and unknown risks, uncertainties and other important factors. Such risks, uncertainties, contingencies and other important factors could cause actual events to differ materially from the expectations expressed or implied in this announcement by such forward-looking statements. PCI Biotech disclaims any obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise.

  This information is subject to the disclosure requirements pursuant to section 5 -12 of the Norwegian Securities Trading Act. PCI Biotech Q2 2017 Report
PCI Biotech Q2 2017 Presentation


This announcement is distributed by Nasdaq Corporate Solutions on behalf of Nasdaq Corporate Solutions clients.

The issuer of this announcement warrants that they are solely responsible for the content, accuracy and originality of the information contained therein.

Source: PCI Biotech Holding via GlobeNewswire
HUG#2129728
GlobeNewswire
globenewswire.com

Last updated on: 30/08/2017

Advertising
Site Map | Privacy & Security | Cookies | Terms and Conditions

PharmiWeb.com is Europe's leading industry-sponsored portal for the Pharmaceutical sector, providing the latest jobs, news, features and events listings.
The information provided on PharmiWeb.com is designed to support, not replace, the relationship that exists between a patient/site visitor and his/her physician.